[
    {
        "pregunta": "1. What is the recommended frequency for screening people with SLE for proteinuria in the absence of known kidney disease?",
        "respuesta": "The recommended frequency for screening individuals with SLE for proteinuria in the absence of known kidney disease is at least every 6-12 months, or when experiencing extra-renal flares. This recommendation is based on the guidelines provided in the retrieved documents.",
        "contexto": [
            "and Treatment Recommendations and Good Practice Statements SCREENING: In people with SLE without known kidney disease, we strongly recommend screening for proteinuria at least every 6-12 months, OR when experiencing extra-renal flares. KIDNEY BIOPSY: GPS: Prompt kidney biopsy should be performed in people with SLE when LN is suspected (unless contraindicated/not feasible). In people with SLE who have proteinuria >0.5 g/g and/or impaired kidney function not otherwise explained, we conditionally",
            "and age-related decline in GFR in this population. MONITORING: In people with LN who have not achieved complete renal response, we strongly recommend quantifying proteinuria at least every 3 months. In people with LN with sustained complete renal response, we strongly recommend quantifying proteinuria every 3-6 months. GPS: In people with LN, serum complement levels and anti-dsDNA antibody concentrations should be checked at every clinic visit but not more frequently than monthly. RENAL",
            "aspirin 81 mg daily as prophylaxis in all patients at high risk for preeclampsia Because active disease affects maternal and pregnancy outcome, we strongly suggest, as good practice, monitoring SLE disease activity with clinical history, examination, and laboratory tests at least once per trimester. Abnormalities in the complete blood cell count, differential cell count, urinalysis results and urinary protein:creatinine ratio, or anti-DNA, C3, or C4 levels may indicate possible SLE flare and/or",
            "LN and significant risk factors for thrombosis (e.g., low serum albumin in context of severe proteinuria) should be discussed with nephrology. IN PEOPLE WITH ACTIVE/NEW ONSET/FLARE OF CLASS III/IV OR CLASS V: …If not on HCQ, we strongly recommend initiation and continuation of HCQ to manage and prevent lupus clinical manifestations, unless contraindicated. …With any elevation in level of proteinuria, including <0.5g/g, we conditionally recommend the addition of RAAS-I. …We conditionally",
            "| |If SLE or SLE-like disease, SS, SSc, or RA: Test once (early) for anti-Ro/SSA and anti-La/SSB [60, 62]|Strong|\n| |If SSc and renal crisis during pregnancy: Treat with ACE inhibitor or ARB for life-threatening disease [55]|Strong|\n|SLE|SLE or SLE-like disease: Test once (early) for aPL (aCL, anti-β₂GPI, LAC) [59, 61]|Strong|\n|Continue HCQ during pregnancy [57]|Strong| |\n|If not taking HCQ, start HCQ during pregnancy if no contraindications [58]|Conditional| |"
        ]
    },
    {
        "pregunta": "2. When is a kidney biopsy strongly recommended in people with SLE suspected of having lupus nephritis?",
        "respuesta": "A kidney biopsy is strongly recommended in people with SLE suspected of having lupus nephritis when the condition is suspected, unless contraindicated or not feasible. This recommendation is based on the guidelines provided in the retrieved documents.",
        "contexto": [
            "and Treatment Recommendations and Good Practice Statements SCREENING: In people with SLE without known kidney disease, we strongly recommend screening for proteinuria at least every 6-12 months, OR when experiencing extra-renal flares. KIDNEY BIOPSY: GPS: Prompt kidney biopsy should be performed in people with SLE when LN is suspected (unless contraindicated/not feasible). In people with SLE who have proteinuria >0.5 g/g and/or impaired kidney function not otherwise explained, we conditionally",
            "and/or impaired kidney function not otherwise explained, we conditionally recommend performing a kidney biopsy. For people with treated LN in remission who present with suspected LN flare (increased proteinuria, hematuria, and/or worsening kidney function), OR for people with ≥6 months of appropriate treatment and ongoing/worsening proteinuria, hematuria, and/or decreased kidney function, we conditionally recommend repeat kidney biopsy. TREATMENT OF ACTIVE LN (CLASS III/IV OR CLASS V): GPS:",
            "(i.e., failed two standard therapy courses), we conditionally recommend treatment escalation to a more intensive regimen, including addition of anti-CD20 agents, or combination therapy with three non-glucocorticoid immunosuppressives (i.e., MPAA, belimumab and CNI), or referral for investigational therapy. OTHER LUPUS KIDNEY DISEASE: GPS: Alternative etiologies of kidney dysfunction in people with SLE should be carefully excluded, including noninflammatory etiologies such as hypertensive,",
            "or early in pregnancy in women with SLE or SLE-like disorders, Sjögren's syndrome, systemic sclerosis, and rheumatoid arthritis. Given the relative persistence and unchanged titers of these antibodies, we strongly recommend against repeating the test during pregnancy. Patients with scleroderma renal crisis. Most diseasespecific recommendations for RMD pregnancy management focus on presence of underlying SLE or positive aPL. One aspect of disease in systemic sclerosis, however, is of particular",
            "and age-related decline in GFR in this population. MONITORING: In people with LN who have not achieved complete renal response, we strongly recommend quantifying proteinuria at least every 3 months. In people with LN with sustained complete renal response, we strongly recommend quantifying proteinuria every 3-6 months. GPS: In people with LN, serum complement levels and anti-dsDNA antibody concentrations should be checked at every clinic visit but not more frequently than monthly. RENAL"
        ]
    },
    {
        "pregunta": "3. What is the preferred therapy regimen for lupus nephritis according to the ACR guideline?",
        "respuesta": "The preferred therapy regimen for lupus nephritis according to the ACR guideline is triple therapy, which includes mycophenolate mofetil or mycophenolic acid (MPAA) regimens over cyclophosphamide regimens, along with the addition of an anti-CD20 agent or combination therapy with three non-glucocorticoid immunosuppressives (MPAA, belimumab, and calcineurin inhibitors). Additionally, a lower glucocorticoid regimen with a prednisone goal of ≤5 mg/day by 6 months of therapy and a total therapy duration of 3-5 years for those achieving complete renal response is recommended.",
        "contexto": [
            "2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis      E755A258B54DE5A9A9F006899726219C This summary was approved by the ACR Board of Directors on November 15, 2024. These recommendations are included in a full manuscript, which will be submitted for publication in Arthritis & Rheumatology and Arthritis Care and Research.  Lupus Nephritis Screening and Treatment Recommendations and Good Practice Statements SCREENING: In",
            "Methodology overview. This guideline followed the American College of Rheumatology (ACR) guideline development process ( http://www.rheumatology.org/Practice-Quality/ Clinical-Support/Clinical-Practice-Guidelines http://onlinelibrary. wiley.com/doi/10.1002/art.40726/abstract http://onlinelibrary.wiley.com/doi/10.1002/art.40726/abstract In addressing pharmacologic therapies, we focused on immunomodulatory agents for long-term management rather than addressing acute symptom management (i.e.,",
            "(i.e., failed two standard therapy courses), we conditionally recommend treatment escalation to a more intensive regimen, including addition of anti-CD20 agents, or combination therapy with three non-glucocorticoid immunosuppressives (i.e., MPAA, belimumab and CNI), or referral for investigational therapy. OTHER LUPUS KIDNEY DISEASE: GPS: Alternative etiologies of kidney dysfunction in people with SLE should be carefully excluded, including noninflammatory etiologies such as hypertensive,",
            "this guideline, we emphasize the importance of prompt kidney biopsy and LN treatment and propose triple therapy as the most desirable therapy for LN, preferring MPAA regimens over CYC regimens. We propose a lower dose glucocorticoid regimen to minimize toxicity, with a prednisone goal of ≤5 mg/day by 6 months of therapy, and a total therapy duration of 3-5 years for those achieving complete renal response. Discussion between clinicians and patients is critical because multiple factors impact",
            "medications in patients with severe SLE would merit review by the treating rheumatologist in consideration of surgery. The Voting Panel agreed with their inclusion via email voting. This guideline is informed by cohort studies including pharmacoepidemiologic studies using large administrative databases. To our knowledge, there have been no randomized controlled trials since the publication of the prior ACR/AAHKS guideline in 2017, so much of the data supporting these recommendations remains"
        ]
    },
    {
        "pregunta": "4. How should medication dosages be adjusted in individuals with decreased GFR at the initiation of lupus nephritis therapy?",
        "respuesta": "Based on the information provided in the retrieved documents, the recommendation for adjusting medication dosages in individuals with decreased GFR at the initiation of lupus nephritis therapy includes:\n\n- For allopurinol, a starting dose of ≤100 mg/day is strongly recommended, and the dose should be lower in patients with CKD (stage ≥3).\n- For febuxostat, a starting dose of ≤40 mg/day is strongly recommended, with subsequent dose titration over starting at a higher dose.\n- For probenecid, a lower starting dose of 500 mg once to twice daily is conditionally recommended, with subsequent dose titration over starting at a higher dose.\n\nIt is essential to consult with a healthcare provider for personalized dosing adjustments based on individual patient factors and specific medical history.",
        "contexto": [
            "LN and significant risk factors for thrombosis (e.g., low serum albumin in context of severe proteinuria) should be discussed with nephrology. IN PEOPLE WITH ACTIVE/NEW ONSET/FLARE OF CLASS III/IV OR CLASS V: …If not on HCQ, we strongly recommend initiation and continuation of HCQ to manage and prevent lupus clinical manifestations, unless contraindicated. …With any elevation in level of proteinuria, including <0.5g/g, we conditionally recommend the addition of RAAS-I. …We conditionally",
            "and MPAA plus CNI. … With proteinuria <1 g/g, we conditionally recommend treatment with glucocorticoids and/or immunosuppressant therapy (MPAA, AZA, or CNI). IN PEOPLE WITH NONRESPONSIVE OR REFRACTORY LN: GPS: Medication dose and patient adherence should be assessed as an important first step in evaluating inadequate response or refractory LN, as insufficient treatment is an important cause of non-response. In people with any LN class with an inadequate renal response (i.e., have not achieved",
            "(i.e., failed two standard therapy courses), we conditionally recommend treatment escalation to a more intensive regimen, including addition of anti-CD20 agents, or combination therapy with three non-glucocorticoid immunosuppressives (i.e., MPAA, belimumab and CNI), or referral for investigational therapy. OTHER LUPUS KIDNEY DISEASE: GPS: Alternative etiologies of kidney dysfunction in people with SLE should be carefully excluded, including noninflammatory etiologies such as hypertensive,",
            "low-dose allopurinol (≤100 mg/day and lower in patients with CKD [stage ≥3] ) and febuxostat (≤40 mg/day) with subsequent dose titration over starting at a higher dose is strongly recommended. Starting treatment with low-dose probenecid (500 mg once to twice daily) with subsequent dose titration over starting at a higher dose is conditionally recommended. A lower starting dose of any ULT reduces the risk of flare associated with initiation Certainty of evidence For patients starting any ULT, we",
            "to target over starting at a higher dose (e.g., <100 mg/day [and lower in patients with CKD] for allopurinol or <40 mg/day for febuxostat). Moderate For probenecid, we conditionally recommend starting at a low dose (500 mg once or twice daily) with dose titration over starting at a higher dose. We strongly recommend initiating concomitant antiinflammatory prophylaxis therapy (e.g., colchicine, NSAIDs, prednisone/prednisolone) over no antiinflammatory prophylaxis. The choice of specific"
        ]
    },
    {
        "pregunta": "5. When should adjunctive treatment with systemic anticoagulation be considered for individuals with lupus nephritis?",
        "respuesta": "I don't have specific information on when adjunctive treatment with systemic anticoagulation should be considered for individuals with lupus nephritis based on the retrieved documents.",
        "contexto": [
            "LN and significant risk factors for thrombosis (e.g., low serum albumin in context of severe proteinuria) should be discussed with nephrology. IN PEOPLE WITH ACTIVE/NEW ONSET/FLARE OF CLASS III/IV OR CLASS V: …If not on HCQ, we strongly recommend initiation and continuation of HCQ to manage and prevent lupus clinical manifestations, unless contraindicated. …With any elevation in level of proteinuria, including <0.5g/g, we conditionally recommend the addition of RAAS-I. …We conditionally",
            "thrombotic event (arterial or venous), regardless of whether they have had obstetric complications; IVIG = intravenous immunoglobulin; PICO = population, intervention, comparator, outcomes. Continue HCQ (if on) LEGEND Against prednisone We recommend that all women with SLE take hydroxychloroquine (HCQ) during pregnancy if possible. If a patient is already taking HCQ, we strongly recommend continuing it during pregnancy; if she is not taking HCQ, we conditionally recommend starting it if there",
            "<h1>Recommendation pertains to infection risk and does not account for risk of cardiac events or venous thromboembolism.</h1>\n\n<h1>RESULTS/RECOMMENDATIONS</h1>\n\n<h1>Table 3. Recommendations for perioperative management of anti-rheumatic drug therapy in patients with inflammatory arthritis and those with systemic lupus erythematosus (SLE) undergoing elective total hip arthroplasty (THA) or total knee arthroplasty (TKA)*</h1>",
            "excluded, including noninflammatory etiologies such as hypertensive, diabetic, and medication-induced nephropathy. ADJUNCTIVE/NON-IMMUNOLOGIC TREATMENT: GPS: Adjunctive and non-immunologic therapies and practices should be initiated in addition to appropriate immunosuppressive therapy to improve overall kidney health. Management of cardiovascular health, bone health, infection risk, and reproductive concerns should be addressed.* GPS: In children with childhood-onset SLE (cSLE) and LN,",
            "additional treatments are needed for patients who do not respond to standard therapy. Intravenous immunoglobuin, low-dose prednisone, increased dose of heparin/LMWH, and HCQ have all been suggested as additional or alternative treatments. We conditionally recommend against treatment with intravenous immunoglobulin or an increased LMWH dose, as these have not been demonstrably helpful in cases of pregnancy loss despite standard therapy with low-dose aspirin and prophylactic heparin or LMWH."
        ]
    },
    {
        "pregunta": "6. What is the recommended duration of therapy for individuals who have achieved sustained complete renal response after treatment with immunosuppressive therapy?",
        "respuesta": "The recommended duration of therapy for individuals who have achieved sustained complete renal response after treatment with immunosuppressive therapy is at least 3-5 years, according to the retrieved documents.",
        "contexto": [
            "recommend a total duration of therapy of at least 3-5 years. IN PEOPLE WITH ACTIVE IN PEOPLE WITH ACTIVE/NEW ONSET/FLARE OF PURE CLASS V: …With proteinuria ≥1 g/g we conditionally recommend treatment with a TRIPLE immunosuppressive regimen consisting of pulse intravenous glucocorticoids 250-1000 mg methylprednisolone daily x 1-3 days, followed by oral glucocorticoid ≤0.5 mg/kg/day (maximum dose 40 mg/day) with taper and MPAA plus CNI. … With proteinuria <1 g/g, we conditionally recommend",
            "we conditionally recommend the addition of RAAS-I. …We conditionally recommend pulse intravenous glucocorticoids 250-1000 mg methylprednisolone daily x 1-3 days, followed by oral glucocorticoid ≤0.5 mg/kg/day (maximum dose 40 mg/day) with taper to a target dose of ≤5mg/day by 6 months. … Who have achieved/sustained a complete renal response after treatment with any (triple or dual) immunosuppressive therapy, we conditionally recommend a total duration of therapy of at least 3-5 years. IN PEOPLE",
            "with impaired vaccine responses Ungraded position statement: The duration of nonglucocor ticoid remission maintenance therapy in GPA/MPA should be guided by the patient's clinical condition, preferences, and values. The optimal duration of remission maintenance therapy is not well established. Although clinical trials have typically administered remission maintenance therapy for ≥18 months, patients may benefit from continuing remission maintenance therapy for a longer duration Ungraded",
            "any LN class with an inadequate renal response (i.e., have not achieved at least a partial renal response by 6-12 months) we conditionally recommend escalation of treatment: • For initial DUAL therapy, escalate to TRIPLE therapy. • For initial TRIPLE therapy, change to an alternative TRIPLE therapy or consider addition of an anti-CD20 agent as a second immunosuppressive. In people with any LN class with refractory disease (i.e., failed two standard therapy courses), we conditionally recommend",
            "this guideline, we emphasize the importance of prompt kidney biopsy and LN treatment and propose triple therapy as the most desirable therapy for LN, preferring MPAA regimens over CYC regimens. We propose a lower dose glucocorticoid regimen to minimize toxicity, with a prednisone goal of ≤5 mg/day by 6 months of therapy, and a total therapy duration of 3-5 years for those achieving complete renal response. Discussion between clinicians and patients is critical because multiple factors impact"
        ]
    },
    {
        "pregunta": "7. In individuals with active or new onset lupus nephritis Class V, what is the recommended treatment for proteinuria levels above 1 g/g?",
        "respuesta": "The recommended treatment for proteinuria levels above 1 g/g in individuals with active or new onset lupus nephritis Class V is to conditionally recommend treatment with a TRIPLE immunosuppressive regimen. This regimen consists of pulse intravenous glucocorticoids (250-1000 mg methylprednisolone daily x 1-3 days) followed by oral glucocorticoid (≤0.5 mg/kg/day, maximum dose 40 mg/day) with taper, mycophenolate mofetil or mycophenolic acid (MPAA), and calcineurin inhibitors (CNI) according to the retrieved documents. Additionally, it is suggested to consult with healthcare providers for personalized treatment recommendations based on individual factors and medical history.",
        "contexto": [
            "LN and significant risk factors for thrombosis (e.g., low serum albumin in context of severe proteinuria) should be discussed with nephrology. IN PEOPLE WITH ACTIVE/NEW ONSET/FLARE OF CLASS III/IV OR CLASS V: …If not on HCQ, we strongly recommend initiation and continuation of HCQ to manage and prevent lupus clinical manifestations, unless contraindicated. …With any elevation in level of proteinuria, including <0.5g/g, we conditionally recommend the addition of RAAS-I. …We conditionally",
            "recommend a total duration of therapy of at least 3-5 years. IN PEOPLE WITH ACTIVE IN PEOPLE WITH ACTIVE/NEW ONSET/FLARE OF PURE CLASS V: …With proteinuria ≥1 g/g we conditionally recommend treatment with a TRIPLE immunosuppressive regimen consisting of pulse intravenous glucocorticoids 250-1000 mg methylprednisolone daily x 1-3 days, followed by oral glucocorticoid ≤0.5 mg/kg/day (maximum dose 40 mg/day) with taper and MPAA plus CNI. … With proteinuria <1 g/g, we conditionally recommend",
            "and Treatment Recommendations and Good Practice Statements SCREENING: In people with SLE without known kidney disease, we strongly recommend screening for proteinuria at least every 6-12 months, OR when experiencing extra-renal flares. KIDNEY BIOPSY: GPS: Prompt kidney biopsy should be performed in people with SLE when LN is suspected (unless contraindicated/not feasible). In people with SLE who have proteinuria >0.5 g/g and/or impaired kidney function not otherwise explained, we conditionally",
            "and MPAA plus CNI. … With proteinuria <1 g/g, we conditionally recommend treatment with glucocorticoids and/or immunosuppressant therapy (MPAA, AZA, or CNI). IN PEOPLE WITH NONRESPONSIVE OR REFRACTORY LN: GPS: Medication dose and patient adherence should be assessed as an important first step in evaluating inadequate response or refractory LN, as insufficient treatment is an important cause of non-response. In people with any LN class with an inadequate renal response (i.e., have not achieved",
            "(i.e., failed two standard therapy courses), we conditionally recommend treatment escalation to a more intensive regimen, including addition of anti-CD20 agents, or combination therapy with three non-glucocorticoid immunosuppressives (i.e., MPAA, belimumab and CNI), or referral for investigational therapy. OTHER LUPUS KIDNEY DISEASE: GPS: Alternative etiologies of kidney dysfunction in people with SLE should be carefully excluded, including noninflammatory etiologies such as hypertensive,"
        ]
    },
    {
        "pregunta": "8. How should non-responsive or refractory lupus nephritis be managed according to the ACR guideline?",
        "respuesta": "In individuals with non-responsive or refractory lupus nephritis, the management should involve assessing medication dose and patient adherence as an important first step in evaluating inadequate response. If there is insufficient treatment leading to non-response, treatment escalation to a more intensive regimen is recommended. This may include adding anti-CD20 agents, combination therapy with three non-glucocorticoid immunosuppressives (such as mycophenolate mofetil or mycophenolic acid, belimumab, and calcineurin inhibitors), or referral for investigational therapy. It is crucial to tailor the treatment approach based on individual patient factors and medical history.",
        "contexto": [
            "and MPAA plus CNI. … With proteinuria <1 g/g, we conditionally recommend treatment with glucocorticoids and/or immunosuppressant therapy (MPAA, AZA, or CNI). IN PEOPLE WITH NONRESPONSIVE OR REFRACTORY LN: GPS: Medication dose and patient adherence should be assessed as an important first step in evaluating inadequate response or refractory LN, as insufficient treatment is an important cause of non-response. In people with any LN class with an inadequate renal response (i.e., have not achieved",
            "2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis      E755A258B54DE5A9A9F006899726219C This summary was approved by the ACR Board of Directors on November 15, 2024. These recommendations are included in a full manuscript, which will be submitted for publication in Arthritis & Rheumatology and Arthritis Care and Research.  Lupus Nephritis Screening and Treatment Recommendations and Good Practice Statements SCREENING: In",
            "(i.e., failed two standard therapy courses), we conditionally recommend treatment escalation to a more intensive regimen, including addition of anti-CD20 agents, or combination therapy with three non-glucocorticoid immunosuppressives (i.e., MPAA, belimumab and CNI), or referral for investigational therapy. OTHER LUPUS KIDNEY DISEASE: GPS: Alternative etiologies of kidney dysfunction in people with SLE should be carefully excluded, including noninflammatory etiologies such as hypertensive,",
            "Methodology overview. This guideline followed the American College of Rheumatology (ACR) guideline development process ( http://www.rheumatology.org/Practice-Quality/ Clinical-Support/Clinical-Practice-Guidelines http://onlinelibrary. wiley.com/doi/10.1002/art.40726/abstract http://onlinelibrary.wiley.com/doi/10.1002/art.40726/abstract In addressing pharmacologic therapies, we focused on immunomodulatory agents for long-term management rather than addressing acute symptom management (i.e.,",
            "any LN class with an inadequate renal response (i.e., have not achieved at least a partial renal response by 6-12 months) we conditionally recommend escalation of treatment: • For initial DUAL therapy, escalate to TRIPLE therapy. • For initial TRIPLE therapy, change to an alternative TRIPLE therapy or consider addition of an anti-CD20 agent as a second immunosuppressive. In people with any LN class with refractory disease (i.e., failed two standard therapy courses), we conditionally recommend"
        ]
    },
    {
        "pregunta": "9. What is the suggested escalation of treatment for individuals with inadequate renal response to initial DUAL therapy?",
        "respuesta": "The suggested escalation of treatment for individuals with inadequate renal response to initial DUAL therapy is to escalate to TRIPLE therapy according to the retrieved documents.",
        "contexto": [
            "any LN class with an inadequate renal response (i.e., have not achieved at least a partial renal response by 6-12 months) we conditionally recommend escalation of treatment: • For initial DUAL therapy, escalate to TRIPLE therapy. • For initial TRIPLE therapy, change to an alternative TRIPLE therapy or consider addition of an anti-CD20 agent as a second immunosuppressive. In people with any LN class with refractory disease (i.e., failed two standard therapy courses), we conditionally recommend",
            "(i.e., failed two standard therapy courses), we conditionally recommend treatment escalation to a more intensive regimen, including addition of anti-CD20 agents, or combination therapy with three non-glucocorticoid immunosuppressives (i.e., MPAA, belimumab and CNI), or referral for investigational therapy. OTHER LUPUS KIDNEY DISEASE: GPS: Alternative etiologies of kidney dysfunction in people with SLE should be carefully excluded, including noninflammatory etiologies such as hypertensive,",
            "While consensus was easily reached on the majority of statements, 2 issues required prolonged discussion and debate. The decision on whether patients with an inadequate response to methotrexate should escalate to a bDMARD, tsDMARD, or triple therapy engendered much discussion with contrasting points of view. In the end, a recommendation was made in favor of a bDMARD or tsDMARD because of the more rapid onset of benefit and concerns related to the poor tolerability and durability of triple",
            "we conditionally recommend the addition of RAAS-I. …We conditionally recommend pulse intravenous glucocorticoids 250-1000 mg methylprednisolone daily x 1-3 days, followed by oral glucocorticoid ≤0.5 mg/kg/day (maximum dose 40 mg/day) with taper to a target dose of ≤5mg/day by 6 months. … Who have achieved/sustained a complete renal response after treatment with any (triple or dual) immunosuppressive therapy, we conditionally recommend a total duration of therapy of at least 3-5 years. IN PEOPLE",
            "2 ), we conditionally recommend preemptive kidney transplant over dialysis or non-preemptive transplant. In people with LN and ESKD, we conditionally recommend proceeding with kidney transplantation without requiring complete clinical or serologic remission, provided there is no other major organ involvement. In people with LN on current dialysis or after kidney transplantation, we strongly recommend regular follow up with rheumatology. Definitions and abbreviations: TRIPLE therapy: GC [pulse"
        ]
    },
    {
        "pregunta": "10. When should referral for investigational therapy be considered in individuals with refractory lupus nephritis?",
        "respuesta": "Referral for investigational therapy should be considered in individuals with refractory lupus nephritis who have not responded adequately to standard therapies, according to the retrieved documents. This recommendation suggests that treatment escalation to a more intensive regimen, such as adding anti-CD20 agents, combination therapy with three non-glucocorticoid immunosuppressives, or referral for investigational therapy, may be necessary for individuals with refractory disease. It is important to consult with healthcare providers for personalized treatment recommendations based on individual factors and medical history.",
        "contexto": [
            "(i.e., failed two standard therapy courses), we conditionally recommend treatment escalation to a more intensive regimen, including addition of anti-CD20 agents, or combination therapy with three non-glucocorticoid immunosuppressives (i.e., MPAA, belimumab and CNI), or referral for investigational therapy. OTHER LUPUS KIDNEY DISEASE: GPS: Alternative etiologies of kidney dysfunction in people with SLE should be carefully excluded, including noninflammatory etiologies such as hypertensive,",
            "LN and significant risk factors for thrombosis (e.g., low serum albumin in context of severe proteinuria) should be discussed with nephrology. IN PEOPLE WITH ACTIVE/NEW ONSET/FLARE OF CLASS III/IV OR CLASS V: …If not on HCQ, we strongly recommend initiation and continuation of HCQ to manage and prevent lupus clinical manifestations, unless contraindicated. …With any elevation in level of proteinuria, including <0.5g/g, we conditionally recommend the addition of RAAS-I. …We conditionally",
            "any LN class with an inadequate renal response (i.e., have not achieved at least a partial renal response by 6-12 months) we conditionally recommend escalation of treatment: • For initial DUAL therapy, escalate to TRIPLE therapy. • For initial TRIPLE therapy, change to an alternative TRIPLE therapy or consider addition of an anti-CD20 agent as a second immunosuppressive. In people with any LN class with refractory disease (i.e., failed two standard therapy courses), we conditionally recommend",
            "and MPAA plus CNI. … With proteinuria <1 g/g, we conditionally recommend treatment with glucocorticoids and/or immunosuppressant therapy (MPAA, AZA, or CNI). IN PEOPLE WITH NONRESPONSIVE OR REFRACTORY LN: GPS: Medication dose and patient adherence should be assessed as an important first step in evaluating inadequate response or refractory LN, as insufficient treatment is an important cause of non-response. In people with any LN class with an inadequate renal response (i.e., have not achieved",
            "medications in patients with severe SLE would merit review by the treating rheumatologist in consideration of surgery. The Voting Panel agreed with their inclusion via email voting. This guideline is informed by cohort studies including pharmacoepidemiologic studies using large administrative databases. To our knowledge, there have been no randomized controlled trials since the publication of the prior ACR/AAHKS guideline in 2017, so much of the data supporting these recommendations remains"
        ]
    }
]